These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2503935)

  • 1. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease.
    Berntorp E; Nilsson IM
    Vox Sang; 1989; 56(4):212-7. PubMed ID: 2503935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.
    Lethagen S; Berntorp E; Nilsson IM
    Ann Hematol; 1992 Dec; 65(6):253-9. PubMed ID: 1457586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A rare hemostatic disorder: pseudo von Willebrand's disease].
    Monrigal C; Fressinaud E; Shoay I; Monrigal JP; Granry JC
    Ann Fr Anesth Reanim; 1989; 8(6):662-6. PubMed ID: 2517382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach of the treatment of von Willebrand's disease during pregnancy.
    Gojnic M; Fazlagic A; Likic I; Stefanovic A; Vidakovic S; Pervulov M; Petkovic S; Mostic T; Miljic P; Bogdanovic A
    Arch Gynecol Obstet; 2005 Nov; 273(1):35-8. PubMed ID: 16172853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease.
    Mazurier C; De Romeuf C; Parquet-Gernez A; Goudemand M
    Eur J Haematol; 1989 Jul; 43(1):7-14. PubMed ID: 2504619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of von Willebrand's disease.
    Mannucci PM
    J Intern Med Suppl; 1997; 740():129-32. PubMed ID: 9350194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
    Weiss HJ; Sussman II; Hoyer LW
    J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ultrapure factor VIII concentrate with double virus inactivation: study of pharmacokinetics in von Willebrand's disease patients].
    Canales Albendea MA; Villar Camacho A; Chamarro Merino G; Magallón Martínez M
    Sangre (Barc); 1998 Feb; 43(1):93-4. PubMed ID: 9577189
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates.
    Berntorp E; Nilsson IM
    Eur J Haematol; 1988 Mar; 40(3):205-14. PubMed ID: 3128452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of von Willebrand's disease. A comparative study of diagnostic tests on nine families with von Willebrand's disease and its differential diagnosis from hemophilia and thrombocytopathy.
    Lian EC; Deykin D
    Am J Med; 1976 Mar; 60(3):344-56. PubMed ID: 1083143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of the severe bleeding episode in type III von Willebrand's disease by simultaneous administration of cryoprecipitate and platelet concentrate.
    Boda Z; Pfliegler G; Hársfalvi J; Rak K
    Blood Coagul Fibrinolysis; 1991 Dec; 2(6):775-7. PubMed ID: 1799664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogens and surgery in women with von Willebrand's disease.
    Alperin JB
    Am J Med; 1982 Sep; 73(3):367-71. PubMed ID: 6981997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.
    Mannuccio Mannucci P; Kyrle PA; Schulman S; Di Paola J; Schneppenheim R; Cox Gill J
    Blood Transfus; 2013 Oct; 11(4):533-40. PubMed ID: 23736911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand's disease: case report and review of literature.
    Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
    Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma.
    Holmberg L; Borge L; Nilsson IM
    Br J Haematol; 1981 Apr; 47(4):587-96. PubMed ID: 6783063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-type von Willebrand's disease.
    Miller JL
    Clin Lab Med; 1984 Jun; 4(2):319-31. PubMed ID: 6437734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.